Idiopathische inflammatorische Myopathien: Aktuelles zu Diagnose und Klassifikation

Zusammenfassung

Auf dem Sektor der Kollagenosen ist der wissenschaftliche Fortschritt bei der Myositis in den letzten 15–20 Jahren bemerkenswert. Durch kontinuierliche Forschung und intensive Vernetzung der Myositis-Experten ist es gelungen, neue Untergruppen zu identifizieren und somit für die Prognose wichtige Organmanifestationen rechtzeitig zu erkennen. Vor dem Hintergrund dieser Neuerungen verfolgt diese Übersichtsarbeit sowohl das Ziel, möglichst alle Facetten der Erkrankung zu präsentieren, als auch die moderne Einteilung der idiopathischen inflammatorischen Myopathien zu erläutern. Außerdem werden die neuen Klassifikationskriterien vorgestellt, die die Kriterien von Bohan und Peter aus dem Jahr 1975 abgelöst haben. Im Artikel werden ihre Stärken und Schwächen sowie ihr Optimierungspotenzial diskutiert.

Abstract

Many publications over the past 15–20 years have shown that there is intense research activity on myositis. Several new subgroups and a number of novel autoantibodies have been identified. This article presents updated knowledge of the myositis disease spectrum, in order to help rheumatologists to recognise muscle inflammation, as well as possible extramuscular organ involvement. Since managing such heterogeneous and rare diseases will remain challenging, correct classification is here the key for successful treatment. After a 13-year development process, the new classification criteria for idiopathic inflammatory diseases are a significant milestone, as they replace those presented by Bohan and Peter in 1975. Part of the aim of this paper is to point out the pros and cons of the new criteria and to discuss potential improvements for the future.

Schlüsselwörter

Myositis - idiopathische inflammatorische Myopathien - Klassifikationskriterien

Keywords

myositis - idiopathic inflammatory myopathy - classification criteria

Publikationsverlauf

Artikel online veröffentlicht:
01. Juli 2021

• Literatur

• 1 Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol 2019; 15: 257-272 DOI: 10.1038/s41584-019-0186-x.
• 2 Glaubitz S, Schmidt K, Zschuntzsch J. et al. Myalgia in myositis and myopathies. Best Pract Res Clin Rheumatol 2019; 33: 101433 DOI: 10.1016/j.berh.2019.101433.
• 3 Stuhlmuller B, Schneider U, Gonzalez-Gonzalez JB. et al. Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies. Front Neurol 2019; 10: 438 DOI: 10.3389/fneur.2019.00438.
• 4 O'Connor A, Mulhall J, Harney SMJ. et al. Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel. Clin Pract 2017; 7: 922 DOI: 10.4081/cp.2017.922.
• 5 Betteridge Z, Tansley S, Shaddick G. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; DOI: 10.1016/j.jaut.2019.04.001.
• 6 Yoshida T, Yoshida M, Mitsuyo K. et al. Dropped Head Syndrome and the Presence of Rimmed Vacuoles in a Muscle Biopsy in Scleroderma-polymyositis Overlap Syndrome Associated with Anti-Ku Antibody. Intern Med 2018; 57: 887-891 DOI: 10.2169/internalmedicine.9363-17.
• 7 Olivier PA, De Paepe B, Aronica E. et al. Idiopathic inflammatory myopathy: Interrater variability in muscle biopsy reading. Neurology 2019; 93: e889-e894 DOI: 10.1212/wnl.0000000000008005.
• 8 Benveniste O, Goebel HH, Stenzel W. Biomarkers in Inflammatory Myopathies-An Expanded Definition. Front Neurol 2019; 10: 554 DOI: 10.3389/fneur.2019.00554.
• 9 Bernardino V, Rodrigues A, Llado A. et al. Nailfold capillaroscopy and autoimmune connective tissue diseases in patients from a Portuguese nailfold capillaroscopy clinic. Rheumatol Int 2020; 40: 295-301 DOI: 10.1007/s00296-019-04427-0.
• 10 Selva-O'Callaghan A, Gil-Vila A, Simó-Perdigó M. et al. PET Scan: Nuclear Medicine Imaging in Myositis. Curr Rheumatol Rep 2019; 21: 64 DOI: 10.1007/s11926-019-0864-3.
• 11 Lilleker JB, Vencovsky J, Wang G. et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018; 77: 30-39 DOI: 10.1136/annrheumdis-2017-211868.
• 12 DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol 2020; 82: 267-281 DOI: 10.1016/j.jaad.2019.06.1309.
• 13 Trallero-Araguás E, Rodrigo-Pendás J, Selva-O'Callaghan A. et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523-532 DOI: 10.1002/art.33379.
• 14 Dani L, Holmqvist M, Martínez MA. et al. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. Clin Exp Rheumatol 2020; 38: 67-73
• 15 Chen Z, Cao M, Plana MN. et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 2013; 65: 1316-1324 DOI: 10.1002/acr.21985.
• 16 Fujimoto M, Watanabe R, Ishitsuka Y. et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol 2016; 28: 636-644 DOI: 10.1097/bor.0000000000000329.
• 17 Rider LG, Shah M, Mamyrova G. et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92: 223-243 DOI: 10.1097/MD.0b013e31829d08f9.
• 18 Klein M, Mann H, Pleštilová L. et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology (Oxford) 2015; 54: 2010-2014 DOI: 10.1093/rheumatology/kev229.
• 19 van der Meulen MF, Bronner IM, Hoogendijk JE. et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61: 316-321
• 20 Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-Mediated Necrotizing Myopathy. Curr Rheumatol Rep 2018; 20: 21 DOI: 10.1007/s11926-018-0732-6.
• 21 Mammen AL, Pak K, Williams EK. et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64: 269-272 DOI: 10.1002/acr.20662.
• 22 Allenbach Y, Mammen AL, Benveniste O. et al. 224^th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018; 28: 87-99 DOI: 10.1016/j.nmd.2017.09.016.
• 23 Tanaka T, Suzuki S, Nishino I. et al. What is the third serological marker associated with immune-mediated necrotizing myopathy?. Scand J Rheumatol 2017; 46: 416-417. DOI: 10.1080/03009742.2016.1258730.
• 24 Stertz G. Polymyositis. Berliner Klinische Wochenschrift 1919; 53: 506 https://archiveorg/details/BerlinerKlinischeWochenschrift191653Teil1/page/n505/mode/2up?q=stertz
• 25 Buchbinder R, Forbes A, Hall S. et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087-1095 DOI: 10.7326/0003-4819-134-12-200106190-00008.
• 26 Limaye V, Luke C, Tucker G. et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013; 33: 965-971 DOI: 10.1007/s00296-012-2489-y.
• 27 András C, Bodoki L, Nagy-Vincze M. et al. Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathol Oncol Res 2019; DOI: 10.1007/s12253-019-00756-4.
• 28 Yang Z, Lin F, Qin B. et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42: 282-291 DOI: 10.3899/jrheum.140566.
• 29 Hill CL, Zhang Y, Sigurgeirsson B. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100. DOI: 10.1016/s0140-6736(00)03540-6.
• 30 Wang J, Guo G, Chen G. et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 2013; 169: 838-847 DOI: 10.1111/bjd.12564.
• 31 Lu X, Yang H, Shu X. et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One 2014; 9: e94128 DOI: 10.1371/journal.pone.0094128.
• 32 Oldroyd A, Sergeant JC, New P. et al. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 2019; 58: 650-655 DOI: 10.1093/rheumatology/key357.
• 33 Cavagna L, Nuno L, Scire CA. et al. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clin Rev Allergy Immunol 2017; 52: 71-80 DOI: 10.1007/s12016-016-8528-9.
• 34 Cavagna L, Trallero-Araguás E, Meloni F. et al. Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med 2019; 8 DOI: 10.3390/jcm8112013.
• 35 Benveniste O, Guiguet M, Freebody J. et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134: 3176-3184 DOI: 10.1093/brain/awr213.
• 36 Lloyd TE, Christopher-Stine L, Pinal-Fernandez I. et al. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken) 2016; 68: 66-71 DOI: 10.1002/acr.22600.
• 37 Griggs RC, Askanas V, DiMauro S. et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-713 DOI: 10.1002/ana.410380504.
• 38 Rose MR. 188^th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 2013; 23: 1044-1055 DOI: 10.1016/j.nmd.2013.08.007.
• 39 Troyanov Y, Targoff IN, Tremblay JL. et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84: 231-249 DOI: 10.1097/01.md.0000173991.74008.b0.
• 40 Nuno-Nuno L, Joven BE, Carreira PE. et al. Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. Int J Rheum Dis 2019; DOI: 10.1111/1756-185x.13559. doi:10.1111/1756-185x.13559
• 41 Betteridge Z, Chinoy H, Vencovsky J. et al. Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology (Oxford) 2020; 59: 1026-1030 DOI: 10.1093/rheumatology/kez406.
• 42 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-407 DOI: 10.1056/nejm197502202920807.
• 43 Tanimoto K, Nakano K, Kano S. et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22: 668-674
• 44 Targoff IN, Miller FW, Medsger TA. et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 527-535 DOI: 10.1097/00002281-199711000-00008.
• 45 Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982 DOI: 10.1016/s0140-6736(03)14368-1.
• 46 Lundberg IE, Tjarnlund A, Bottai M. et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol 2017; 69: 2271-2282 DOI: 10.1002/art.40320.
• 47 Barsotti S, Dastmalchi M, Notarnicola A. et al. Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. Semin Arthritis Rheum 2019; DOI: 10.1016/j.semarthrit.2019.12.001.
• 48 Jinnin M, Ohta A, Ishihara S. et al. First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Ann Rheum Dis 2020; 79: 387-392 DOI: 10.1136/annrheumdis-2019-215488.
• 49 To F, Parker MJS, Ventín-Rodríguez C. et al. Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. Rheumatology (Oxford) 2019; 58: 2331-2333 DOI: 10.1093/rheumatology/kez253.
• 50 Parker MJS, Oldroyd A, Roberts ME. et al. The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. Rheumatology (Oxford) 2019; 58: 468-475 DOI: 10.1093/rheumatology/key343.
• 51 Luu Q, Day J, Hall A. et al. External Validation and Evaluation of Adding MRI or Extended Myositis Antibody Panel to the 2017 EULAR/ACR Myositis Classification Criteria. ACR Open Rheumatol 2019; 1: 462-468 DOI: 10.1002/acr2.11061.